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Abstract
Anti-apoptotic Bcl-2 proteins are upregulated in different cancers, including diffuse large B-cell lymphoma (DLBCL) and
chronic lymphocytic leukemia (CLL), enabling survival by inhibiting pro-apoptotic Bcl-2-family members and inositol
1,4,5-trisphosphate (IP3) receptor (IP3R)-mediated Ca
2+-signaling. A peptide tool (Bcl-2/IP3R Disruptor-2; BIRD-2) was
developed to abrogate the interaction of Bcl-2 with IP3Rs by targeting Bcl-2′s BH4 domain. BIRD-2 triggers cell death in
primary CLL cells and in DLBCL cell lines. Particularly, DLBCL cells with high levels of IP3R2 were sensitive to BIRD-2.
Here, we report that BIRD-2-induced cell death in DLBCL cells does not only depend on high IP3R2-expression levels, but
also on constitutive IP3 signaling, downstream of the tonically active B-cell receptor. The basal Ca
2+ level in SU-DHL-4
DLBCL cells was signiﬁcantly elevated due to the constitutive IP3 production. This constitutive IP3 signaling fulﬁlled a pro-
survival role, since inhibition of phospholipase C (PLC) using U73122 (2.5 µM) caused cell death in SU-DHL-4 cells.
Milder inhibition of IP3 signaling using a lower U73122 concentration (1 µM) or expression of an IP3 sponge suppressed
both BIRD-2-induced Ca2+ elevation and apoptosis in SU-DHL-4 cells. Basal PLC/IP3 signaling also fulﬁlled a pro-survival
role in other DLBCL cell lines, including Karpas 422, RI-1 and SU-DHL-6 cells, whereas PLC inhibition protected these
cells against BIRD-2-evoked apoptosis. Finally, U73122 treatment also suppressed BIRD-2-induced cell death in primary
CLL, both in unsupported systems and in co-cultures with CD40L-expressing ﬁbroblasts. Thus, constitutive IP3 signaling in
lymphoma and leukemia cells is not only important for cancer cell survival, but also represents a vulnerability, rendering
cancer cells dependent on Bcl-2 to limit IP3R activity. BIRD-2 seems to switch constitutive IP3 signaling from pro-survival
into pro-death, presenting a plausible therapeutic strategy.
Introduction
Different malignancies, including B-cell cancers such as
diffuse large B-cell lymphoma (DLBCL), are characterized
by overexpression of the anti-apoptotic Bcl-2 protein [1].
This proto-oncogene is localized at the mitochondria and at
the endoplasmic reticulum (ER). At the level of the mito-
chondria, Bcl-2 binds to and neutralizes pro-apoptotic BH3-
only proteins via its hydrophobic cleft, thereby preventing
Bak/Bax activation and mitochondrial outer membrane
permeabilization [2]. BH3-mimetic compounds, like vene-
toclax, counteract Bcl-2′s anti-apoptotic function at the
mitochondria [3]. These molecules trigger apoptosis in
cancer cells that are primed to death due to high levels of
Bax or Bim, and thus are addicted to Bcl-2 for their survival
[4, 5].
However, some cancer cells with high Bcl-2 levels
respond poorly to BH3 mimetics [6–9], suggesting that Bcl-
2 promotes cell survival via a different mechanism. Indeed,
the last decades, Bcl-2 proteins emerged as critical
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modulators of intracellular Ca2+ dynamics [10, 11]. As
such, Bcl-2 also acts at the ER Ca2+ stores where it inhibits
inositol 1,4,5-trisphosphate (IP3) receptors (IP3Rs), a major
class of intracellular Ca2+-release channels [12, 13]. Bcl-2
impacts IP3Rs by binding with its N-terminal BH4 domain
to the central, modulatory domain of the channel [14–16].
Furthermore, Bcl-2′s C-terminal transmembrane domain
enables efﬁcient IP3R inhibition within cells [17]. A
cell-permeable peptide tool named Bcl-2/IP3R Disruptor-2
(BIRD-2) was developed, capable of stripping Bcl-2 from
IP3Rs [18]. In contrast, the BH3-mimetic Bcl-2 inhibitor
venetoclax is not able to disrupt Bcl-2/IP3R complexes [19].
In chronic lymphocytic leukemia (CLL) and DLBCL,
BIRD-2 triggered pro-apoptotic Ca2+-release events,
while sparing normal peripheral mononuclear blood cells
[18, 20].
In a collection of DLBCL cell lines, we previously
identiﬁed IP3R2-expression levels as an important deter-
minant underlying BIRD-2 sensitivity [20]. Here, we
investigated whether IP3R2 levels are the only determinant
that dictates the BIRD-2 sensitivity of B-cell cancers. Of
note, IP3R2 is the IP3R isoform that displays the highest
sensitivity to its ligand IP3 [21, 22]. Interestingly, B-cell
cancers, including DLBCL and CLL, display constitutive
B-cell receptor (BCR) signaling [23–25]. A cascade of
signaling proteins becomes activated downstream of the
BCR, including phospholipase C gamma 2 (PLCγ2), which
hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2)
Fig. 1 High IP3R2-expression
levels are not sufﬁcient per se to
render cells sensitive to BIRD-2.
a The IP3R2- and Bcl-2-protein
levels present in cell lysates
from SU-DHL-4 (40 µg), OCI-
LY-1 (40 µg), and HepG2 (40
µg) cells and from microsomes
extracted from primary
hepatocytes (20 µg) were
determined by western-blot
analysis. The expression level of
calnexin was used as a control
for equal loading.
b Representative dot plots from
ﬂow cytometry analysis
measuring apoptosis by staining
SU-DHL-4, OCI-LY-1, HepG2
cells and primary hepatocytes
with Annexin V-FITC and 7-
AAD. Cells were treated with
vehicle or 10 μM BIRD-2 for
2 h. The dot plots are
representative of 3 independent
experiments. c, d Quantitative
analysis of 3 independent
experiments detecting apoptosis
in Annexin V-FITC/7-AAD-
stained cells treated with vehicle
or 10 µM BIRD-2. Apoptotic
cell death was measured 2 h (c)
and 24 h (d) after BIRD-2
treatment. Data are represented
as average ± SEM (N= 3).
Statistically signiﬁcant
differences were determined
with a Student’s t-test (paired,
two-tailed, *P < 0.05) (BIRD-2
versus vehicle)
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into IP3. We investigated whether constitutive PLCγ2/IP3
signaling occurs in B-cell cancer models and whether this
contributes to survival and BIRD-2 sensitivity in DLBCL
with elevated IP3R2-expression levels. Our results indicate
that cancer cells are addicted to Bcl-2 acting at the ER Ca2+
stores to regulate IP3R-mediated Ca
2+ release. We found
that disrupting the Bcl-2/IP3R interaction with BIRD-2
switched Ca2+ signaling within cancer cells from pro-
survival to pro-death, resulting in cancer cell death.
Results
IP3R2 expression is necessary but not sufﬁcient for
sensitivity to BIRD-2
Since the sensitivity of DLBCL cell lines to BIRD-2 cor-
related to IP3R2-expression levels [20], we questioned
whether IP3R2 expression is sufﬁcient to dictate BIRD-2
sensitivity. Via western-blot analysis, we measured the
expression levels of IP3R2 and Bcl-2 in microsomes pre-
pared from primary hepatocytes, which have a high IP3R2
density [26–28], in human liver carcinoma HepG2 cells and
in the BIRD-2-sensitive (SU-DHL-4) and BIRD-2-resistant
(OCI-LY-1) DLBCL cell lines (Fig. 1a). This analysis
revealed that IP3R2 is expressed in SU-DHL-4 and HepG2
cells, as well as in primary hepatocytes, while IP3R2 is
virtually absent in OCI-LY-1 (Fig. 1a). Furthermore, the
DLBCL cell lines expressed high levels of the anti-
apoptotic Bcl-2 protein, whereas Bcl-2 expression was
very low in the HepG2 cells or even absent in the liver
microsomes (Fig. 1a). We next asked whether HepG2
cancer cells and primary hepatocytes are sensitive to BIRD-
2. Therefore, apoptosis was measured in the four different
cell types after 2 and 24 h of BIRD-2 (10 µM) treatment
(Fig. 1b-d). BIRD-2 induced cell death in about 50% of the
SU-DHL-4 cells, whereas OCI-LY-1 cells were not sensi-
tive to 10 µM BIRD-2. In HepG2 cells, BIRD-2 induced
apoptosis in approximately 20% of the population, sug-
gesting that tumorigenic cells expressing IP3R2 display
BIRD-2 sensitivity. To further substantiate the importance
of IP3R2 for BIRD-2 sensitivity, primary hepatocytes were
treated with 10 µM BIRD-2. Despite expression of IP3R2
(Fig. 1a), the hepatocytes were resistant to BIRD-2-induced
Fig. 2 SU-DHL-4 cells display constitutive IP3/Ca
2+ signaling. a The
basal Ca2+ level was used as a read-out for measuring the level of
constitutive IP3 signaling downstream the BCR, which has been
reported to be tonically active in germinal center DLBCL (BCR*)
[23–25]. PLC activity was suppressed using U73122, whereas its
inactive enantiomer U73343 did not affect PLC activity. b A typical
ﬂuorescent recording of the basal [Ca2+]cyt in SU-DHL-4 cells pre-
treated with vehicle (black line), 1 μM U73122 (red line) or 1 µM
U73343 (gray line) using the ratiometric Ca2+ indicator Fura-2 AM.
The cells were present in Krebs medium supplemented with 1.5 mM
CaCl2. The ratio of emitted ﬂuorescence of Fura-2 (F340/F380) was
monitored and Ca2+ values were calibrated by adding digitonin (50
µM) and a 20-fold excess of EGTA (33 mM) to determine Rmax and
Rmin respectively (see Method section). Basal [Ca
2+] (nM) are reported
in c as the mean ± SEM (N= 5). The exact values of each independent
experiment are represented in different colors. Statistically signiﬁcant
differences were determined using an analysis of variance (ANOVA,
**P < 0.01, ***P < 0.001)
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apoptosis (Fig. 1b-d). Consistent with our previous ﬁndings
[20], these data indicate that IP3R2 expression is required
for BIRD-2-evoked apoptosis since tumorigenic
cells lacking IP3R2 (OCI-LY-1) were resistant to BIRD-2,
whilst tumorigenic cells expressing IP3R2 (SU-DHL-4)
were sensitive. However, IP3R2 expression per se is
not sufﬁcient for BIRD-2-evoked cell death, since
hepatocyte cell viability was not signiﬁcantly affected by
BIRD-2.
SU-DHL-4 cells display enhanced basal IP3 signaling
Since the BCR is tonically active in DLBCL cells and
since the BCR signalosome activates PLCγ2 [23–25], we
investigated whether the BIRD-2 sensitive SU-DHL-4 cell
line displayed elevated constitutive IP3 signaling. As a
read-out for constitutive IP3 signaling, we monitored the
cytosolic Ca2+ concentration ([Ca2+]cyt) with Fura-2 in
SU-DHL-4 cells pre-treated with vehicle, the PLC
inhibitor U73122 or its inactive enantiomer U73343
(Fig. 2a-b). The basal [Ca2+]cyt in vehicle-treated
SU-DHL-4 cells was 59 ± 6.3 nM, which was lowered
to 32 ± 5.6 and 38 ± 4.5 nM upon treatment with 1 and
2.5 μM U73122, respectively, while U73343 was without
effect (Fig. 2c). Taken together, these results indicate that
SU-DHL-4 cells are characterized by a constitutively
active IP3 signaling, likely downstream to tonic BCR
signaling.
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PLC inhibition suppresses BIRD-2-induced apoptosis
in SU-DHL-4 cells
To assess the contribution of IP3 signaling to BIRD-2-
induced cell death, we blocked PLC signaling with
U73122 in SU-DHL-4. In these cells, U73122 suppressed
IP3-induced Ca
2+ release, since the anti-IgG/M-provoked
cytosolic Ca2+ response was reduced in cells pre-treated
for 30 min with 1 and 2.5 µM U73122, compared to
vehicle- or U73343-treated cells (Fig. 3a). This Ca2+
response was quantiﬁed by measuring the area under the
curve (AUC), which was signiﬁcantly reduced upon
treatment with U73122 (2.5 µM) (Fig. 3b). Next, it was
determined whether PLC inhibition by itself impacted SU-
DHL-4 survival by treating them for 30 min, 2 h or 24 h
with different concentrations of U73122 (0.1, 0.5, 1, and
2.5 µM) or U73343. Interestingly, the highest concentra-
tions of U73122 (1 and 2.5 µM), but not its inactive
enantiomer, induced apoptotic cell death in SU-DHL-4
cells (Fig. 3c). These data indicate that PLC signaling has
a pro-survival role in DLBCL cells. Subsequently, it was
determined whether PLC inhibition protected against
BIRD-2-induced cell death in SU-DHL-4 cells. Therefore,
apoptosis induced by 10 µM BIRD-2 was measured in
cells pre-treated for 30 min with vehicle, U73122 or
U73343 (Fig. 3d). After 2 h (Fig. 3e) and 24 h (Fig. 3f ) of
peptide treatment, U73122 signiﬁcantly protected SU-
DHL-4 cells against BIRD-2-triggered apoptosis, while
U73343 did not. Of note, since U73122 provoked cell
death by itself, the Δ apoptotic fraction was calculated
for each condition (Fig. 3e,f ). The Δ apoptotic fraction
was obtained by subtracting the % of cells undergoing cell
death in U73122-treated conditions from the % of cells
undergoing cell death upon BIRD-2+U73122 treatment
(Fig. 3d).
To exclude that the protective effect of U73122 against
BIRD-2-induced apoptosis was due to the artifact that less
living cells were available for BIRD-2 upon U73122
treatment, we performed cell death assays in which SU-
DHL-4 cells were treated with U73122 in combination with
venetoclax, a Bcl-2-selective BH3-mimetic drug that pro-
vokes cell death independently of Ca2+ overload [19]. If
U73122 and venetoclax work independently, the effect
should be additive, providing a clear distinction with the
data obtained with BIRD-2. After 24 h of venetoclax
treatment, approximately 60% of the cells were alive
(Fig. 3g). Combined treatment of venetoclax with U73122
(1 and 2.5 µM) further decreased the percentage of living
cells compared to single treatment with venetoclax due to
the cell death induced by U73122, while U73343 did not
display this effect. In contrast, BIRD-2-induced cell death
was decreased in combination with the PLC inhibitor,
indicating that U73122 protected against BIRD-2-triggered
apoptosis (Fig. 3g). Thus, the reduction in BIRD-2-induced
cell death provoked by PLC inhibition is not due to a
decreased availability of living cells upon U73122
treatment. To substantiate this further, we calculated
the combination index (CI), which quantiﬁes whether a
drug combination is synergistic (CI < 0.8), additive
(0.8 ≤CI ≤ 1.2), or antagonistic (CI > 1.2) (Fig. 3h). The CI
for the combined treatment of venetoclax with U73122 was
approximately 1, indicating this drug combination is addi-
tive. In contrast, combined treatment of U73122 with
BIRD-2 resulted in a CI of around 1.7, indicating an
antagonistic drug combination. Hence, the Δ apoptotic
fraction provides a bona ﬁde analysis for the protective
effects of U73122 against BIRD-2-induced cell death
(Fig. 3e,f ).
Fig. 3 U73122 protects against BIRD-2-triggered apoptosis in SU-
DHL-4. a Cell-population analysis of the cytosolic Ca2+ response,
measured with Fura-2 AM, in SU-DHL-4 cells pre-treated for 30 min
with U73122 (1 and 2.5 µM), U73343 (2.5 µM) or vehicle (DMSO).
Addition of 3 mM EGTA and 12 µg/ml anti-IgG/M antibody is indi-
cated by the ﬁrst and second arrow, respectively. The curves are
representative of 3 independent experiments. The cytosolic Ca2+
response after anti-IgG/M addition was quantiﬁed by measuring the
area under the curve (AUC), which is shown in b. c Quantitative
analysis of 3 independent experiments detecting apoptosis in Annexin
V-FITC/7-AAD-stained SU-DHL-4 cells. Cells were treated with
varying concentrations of U73122 or 2.5 µM U73343. Apoptotic cell
death was measured 30 min, 2 h and 24 h after treatment. On the y-axis
the percentage of living cells is plotted. Data are shown as the average
± SEM (N= 3). d Representative dot plots from ﬂow cytometry ana-
lysis detecting apoptosis in Annexin V-FITC/7-AAD-stained SU-
DHL-4 cells treated for 2 h with vehicle or 10 µM BIRD-2. Cells were
pre-treated for 30 min with U73122 or U73343. e, f Quantitative
analysis of 4 independent experiments detecting apoptosis in Annexin
V-FITC/7-AAD-stained SU-DHL-4 cells. Apoptotic cell death was
measured as the percentage of Annexin V-FITC-positive cells. Cells
were pre-treated with U73122 or U73343 for 30 min. Cell death was
measured 2 h (e) and 24 h (f) after BIRD-2 treatment. On the y-axis,
the Δ apoptotic fraction is plotted, which is the difference in apoptosis
between the BIRD-2-treated and the vehicle-treated fraction, and
between the BIRD-2+U73122-treated and the U73122-treated frac-
tion, and ﬁnally between the BIRD-2+U73343-treated and the
U73343-treated fraction. Data are shown as the average ± SEM (N=
5). g Quantitative analysis of 4 independent experiments detecting
apoptosis in Annexin V-FITC/7-AAD-stained SU-DHL-4 cells treated
with 1 or 2.5 µM U73122, 2.5 µM U73343, 5 µM BIRD-2 (blue), 3 µM
venetoclax (green) or a combination of U73122/U73343 with BIRD-2/
venetoclax. For the conditions without Bcl-2 inhibitor (indicated with
a ‘-’), the green bars indicate the use of the vehicle control for vene-
toclax, while the blue bars indicate the use of vehicle control for
BIRD-2 treatment. A ‘+’ indicates that the Bcl-2 inhibitor (BIRD-2/
venetoclax) was added in this condition. Cell death was measured 24 h
after treatment. On the y-axis the percentage of living cells, which
corresponds to the Annexin V-FITC- and 7-AAD-negative fraction, is
shown. Data are expressed as the average ± SEM (N= 4). h CI derived
from SU-DHL-4 cells treated with U73122/U73343 in combination
with BIRD-2/venetoclax. The CI was calculated (see Method section)
from the data shown in g. Statistically signiﬁcant differences were
determined using an analysis of variance (ANOVA, *P < 0.05, **P <
0.01, ***P < 0.001)
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Thus, these data indicate that PLC activity contributes to
BIRD-2-induced DLBCL cancer cell death. This suggests
that disrupting Bcl-2/IP3R complexes results in excessive,
pro-apoptotic Ca2+ signals that are driven by endogenous
IP3 signaling, whereby Bcl-2 suppresses such pro-death
Ca2+ ﬂuxes by tuning-down IP3R activity. Moreover, the
increased basal PLC activity in DLBCL cells is a pro-
survival signal, which can be changed to pro-death signal-
ing by BIRD-2.
PLC inhibition blunts the BIRD-2-induced cytosolic
[Ca2+] rise in SU-DHL-4 cells
Next, we investigated in more depth how PLC inhibition
prevented the BIRD-2-evoked death of SU-DHL-4 cells.
As reported previously [20], BIRD-2 caused an IP3R-
dependent increase in cytosolic Ca2+ levels in SU-DHL-4
cells. Here, we assessed BIRD-2-induced Ca2+ elevations in
Fura-2-loaded SU-DHL-4 cells in the presence of U73122
using single cell (Fig. 4a,b) and cell population (Fig. 4c,d)
Ca2+ measurements. BIRD-2, but not a TAT-control pep-
tide, caused a rise in the cytosolic Ca2+ levels in SU-DHL-4
single cells as measured by ﬂuorescence microscopy. This
Ca2+ rise was less prominent in cells pre-treated with 1 μM
U73122, but not with U73343 (Fig. 4a,b). Similar ﬁndings
were obtained in SU-DHL-4 cell populations analyzed using
a FlexStation 3 microplate reader (Fig. 4c). The peak
amplitude of the BIRD-2-evoked Ca2+ rise was signiﬁcantly
lower in SU-DHL-4 cells pre-treated with 1 µM U73122
compared to cells treated with vehicle or U73343 (Fig. 4d).
Fig. 4 U73122 reduces the BIRD-2-induced cytosolic Ca2+ rise in SU-
DHL-4 cells. a Single-cell analysis of the BIRD-2-induced Ca2+
response in SU-DHL-4 cells using the ratiometric Ca2+ indicator Fura-
2 AM. Representative pseudo-color images before (2 s) and after
(500 s) BIRD-2 treatment are shown. Vehicle and TAT-Ctrl were used
as negative control conditions. The pseudo-color scale bar indicates
increasing ratio ﬂuorescence. b Single-cell cytosolic Ca2+ signals
(gray lines) and their respective mean (black line) upon addition of
vehicle, TAT-ctrl peptide or 10 µM BIRD-2 to SU-DHL-4 cells
without or with pre-treatment of 1 μM U73122/U73343. c Cell-
population analysis of the cytosolic Ca2+ response induced by 10 µM
BIRD-2 in SU-DHL-4 cells pre-treated without (black line) or with 1
µM U73122 (green line) or 1 µM U73343 (gray line). The curves are
representative of 4 independent experiments. Data were quantiﬁed by
calculating the peak amplitude (d). In d, data are represented as mean
± SEM (N= 4). Statistically signiﬁcant differences were determined
using an analysis of variance (ANOVA, *P < 0.05)
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Buffering intracellular IP3 suppresses BIRD-2-
induced apoptosis in SU-DHL-4 cells
Next, we aimed to conﬁrm these ﬁndings by transfecting
SU-DHL-4 cells with a high-afﬁnity IP3 sponge that efﬁ-
ciently buffers intracellular IP3 [29]. Of note, approxi-
mately 40% of the SU-DHL-4 cells could be successfully
transfected with our transfection method (Fig. 5a). BIRD-
2-induced apoptosis was reduced in SU-DHL-4 cells
expressing the IP3 sponge compared to mock-transfected
or empty vector-transfected cells (Fig. 5b,c). The Δ
apoptotic fraction was approximately 22 and 16% in
mock-transfected cells and SU-DHL-4 cells expressing a
control vector, respectively (Fig. 5c). In contrast, the Δ
apoptotic fraction was only around 10% in SU-DHL-4
cells expressing the IP3 sponge. We also performed single-
cell Ca2+ measurements, in which cells expressing the IP3
sponge displayed reduced BIRD-2-induced Ca2+ signals
compared to empty vector-expressing cells (Fig. 5d).
Hence, our pharmacological (U73122) and genetic (IP3
sponge) approaches indicate that constitutive IP3 signaling
is an important determinant underlying BIRD-2 sensitivity
in DLBCL. Moreover, the effect of the IP3 sponge
demonstrates that IP3, rather than another messenger
arising from upstream PLC activity, is critical for BIRD-2-
evoked cell death.
Pharmacological PLC inhibition also suppresses
BIRD-2-induced apoptosis in other DLBCL cell lines
It was examined whether constitutive IP3 signaling also
contributes to BIRD-2-triggered apoptosis in other DLBCL
cell lines besides SU-DHL-4, including Karpas 422 and SU-
DHL-6 as germinal center DLBCL and RI-1, characterized
as activated B-cell DLBCL. First, the U73122 sensitivity of
these cells was determined by measuring apoptosis 24 h
after treatment with U73122 (1 or 2.5 µM) or U73343 (2.5
µM) (Fig. 6a-c). U73122, but not the inactive enantiomer,
induced cell death in the three cell lines. U73122-triggered
apoptosis was the lowest in SU-DHL-6 (Fig. 6a), whereas
RI-1 cells (Fig. 6c) were the most sensitive to PLC inhibi-
tion. These results indicate that all three DLBCL cell lines,
like the SU-DHL-4 cells, depend on constitutive PLC/IP3
signaling for their survival. Next, it was investigated whe-
ther BIRD-2-induced apoptosis depends on this constitutive
IP3 signaling (Fig. 6). In each cell line, the IC50 value of
BIRD-2, previously determined in a subset of DLBCL [9],
was used. This corresponds to 15 µM BIRD-2 for SU-DHL-
6 (Fig. 6a-e) and Karpas 422 cells (Fig. 6b-f), and 26 µM for
RI-1 (Fig. 6c-g). To determine U73122-mediated protection
against BIRD-2 in these cell lines, the Δ apoptotic fraction
was used. This analysis was again validated using veneto-
clax (Fig. 6a-d) as before (Fig. 3g-h), showing that U73122
treatment displayed additive cell-death effects with vene-
toclax, whereas U73122+BIRD-2 is an antagonistic drug
combination (Fig. 6d). In all three cell lines tested, BIRD-2-
induced cell death was signiﬁcantly suppressed by U73122
(Fig. 6e-g). In conclusion, these data indicate that not only
SU-DHL-4 but also other DLBCL cell lines depend on
constitutive IP3 signaling for their survival, and that this
pro-survival signaling can be turned into pro-death signal-
ing by BIRD-2.
Pharmacological PLC inhibition suppresses BIRD-2-
induced apoptosis in primary CLL patient cells
Finally, we aimed to translate our ﬁndings to primary
peripheral blood cells obtained from patients diagnosed
with CLL, another B-cell malignancy characterized by
constitutively active BCR signaling. BIRD-2 (30 µM)
treatment for 2 h triggered apoptosis in all 14 CLL samples
analyzed, though with potencies ranging from ~20% to
~70% of the cells being apoptotic (Fig. 7). To assess
whether IP3 signaling contributes to the BIRD-2 response
in the CLL cells, BIRD-2-triggered apoptosis was mea-
sured in samples pre-treated for 30 min with U73122. The
lowest U73122 concentration for which an effect could be
observed was used in each sample (0.1/0.5/2.5 µM, Sup-
plemental Table 1). The CLL patient samples were strati-
ﬁed in groups according to their sensitivity towards
U73122 and to the CI calculated for the combined treat-
ment of U73122 with BIRD-2. In this way, four different
groups are recognized: CI > 1.2 and cell death U73122 <
10% (Fig. 7a), CI > 1.2 and cell death U73122 > 10%
(Fig. 7b), 0.8 ≤ CI ≤ 1.2 (Fig. 7c), and CI < 0.8 (Fig. 7d). In
9 out of 14 CLL samples, we found that the drug combi-
nation was antagonistic (CI > 1.2), suggesting that PLC
inhibition protected against BIRD-2-induced apoptosis.
However, because the CLL cells displayed varying sensi-
tivity to U73122, the samples were further subdivided
according to U73122-induced cell death. U73122 did not
induce apoptosis in 5 of these samples (Fig. 7a), whereas
cell viability of the other 4 samples was reduced by PLC
inhibition (Fig. 7b). To determine whether U73122 sig-
niﬁcantly protected against BIRD-2-induced apoptosis in
these groups, the Δ apoptotic fraction for BIRD-2-treated
and U73122+ BIRD-2-treated cells was calculated (Sup-
plemental Table 1). This analysis indicates that
U73122 signiﬁcantly protected against BIRD-2-induced
apoptosis in both groups (Fig. 7a-b). Next, in 2 out of 14
CLL samples, U73122 did not protect against BIRD-2
(0.8 ≤ CI ≤ 1.2) (Fig. 7c), whereas in 3 out of 14 samples
BIRD-2-induced apoptosis was even increased by U73122
(CI < 0.8) (Fig. 7d). The Δ apoptotic fraction analysis was
also validated for these CLL samples using venetoclax
(Supplemental Fig. 1).
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Finally, we measured the effect of U73122 on the
BIRD-2 response in CLL cells co-cultured with CD40L-
expressing ﬁbroblasts to allow for longer BIRD-2 treat-
ments. Co-cultured CLL cells were treated for 20 h with
BIRD-2 and/or U73122, after which the cells were col-
lected and cell viability was assessed. Co-cultured CLL
cells appeared better protected from spontaneous apoptosis
than CLL cells in non-supported cultures (Fig. 8a). In
these co-cultured CLL cells, BIRD-2 remained capable to
induce cell death and PLC inhibitor U73122 signiﬁcantly
reduced BIRD-2-induced apoptosis (Fig. 8b). Thus, CLL
cells in both unsupported and supported cultures share a
common sensitivity to BIRD-2, as disruption of the Bcl-2/
IP3R interaction leads to death of the primary cells. Fur-
thermore, in most CLL patient samples suppressing basal
PLC activity with U73122 protected against BIRD-2-
induced apoptosis. However, for some CLL cells,
enhanced basal PLC signaling is very critical for their
survival, and solely inhibiting PLC is sufﬁcient to cause
cell death.
Fig. 5 SU-DHL-4 cells are protected from BIRD-2-triggered apoptosis
by genetically manipulating the IP3 signaling pathway. a Examples of
ﬂow cytometry analysis showing the percentage of GFP-positive
transfected SU-DHL-4 cells, visible as a shift in the BL-1
(515–545 nm) channel, while the values in the BL-3 (665–715 nm)
channel remained unaffected. b Representative ﬂow cytometry ana-
lysis of BIRD-2-induced apoptosis in SU-DHL-4 cells transfected with
the IP3 sponge or a control vector compared to mock-transfected cells.
Apoptosis was detected via Annexin V-APC-positive staining (RL1+
= red laser, see Method section) of the cells. c Quantiﬁcation of the
apoptotic fraction (%) after treatment with 10 µM BIRD-2 (red
histogram in panel b) or vehicle (black histogram panel b) in mock-
transfected SU-DHL-4 cells or cells transfected with the IP3 sponge or
a control vector. Apoptotic cells were identiﬁed as the Annexin V-
APC-positive fraction (RL1+). Data are represented as mean ± SEM of
3 independent experiments. d Single-cell cytosolic Ca2+ measure-
ments performed in SU-DHL-4 cells utilizing Fura-2 AM. Cells were
transfected with an IP3 sponge vector or with an empty vector as
negative control condition (pcDNA3.1). The addition of 10 µM BIRD-
2 is indicated by the arrow. Data are represented as the average ± SEM
of 3 independent experiments (n > 100 cells/condition)
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Fig. 6 PLC inhibition also suppresses BIRD-2-triggered apoptosis in
other DLBCL cell lines. a, b, c Quantitative analysis of at least 3
independent experiments detecting apoptosis in Annexin V-FITC/7-
AAD-stained SU-DHL-6 (a), Karpas 422 (b), and RI-1 (c) cells treated
with U73122, U73343, BIRD-2 (blue), venetoclax (green) or a com-
bination of U73122/U73343 with BIRD-2/venetoclax. For the condi-
tions without Bcl-2 inhibitor (indicated with a ‘-’), the green bars
indicate the use of the vehicle control for venetoclax, while the blue
bars indicate the use of vehicle control for BIRD-2 treatment. A ‘+’
indicates that the Bcl-2 inhibitor (BIRD-2/venetoclax) was added in
this condition. SU-DHL-6 and Karpas 422 cells were treated with
15 µM BIRD-2, whereas 26 µM BIRD-2 was used to treat the RI-1
cells. SU-DHL-6 cells were treated with 500 nM venetoclax, Karpas
422 cells with 1 µM venetoclax and RI-1 cells were treated with 10 nM
venetoclax. Cell death was measured 24 h after treatment. On the y-
axis the percentage of living cells, which corresponds to the Annexin
V-FITC- and 7-AAD-negative fraction, is shown. Data are expressed
as the average ± SEM (N ≥ 3). d CI derived from cells treated with
U73122/U73343 in combination with BIRD-2/venetoclax. The CI was
calculated from the data shown in a, b, c. e, f, g Quantitative analysis
of 4 independent experiments detecting apoptosis in Annexin V-FITC/
7-AAD-stained SU-DHL-6 (e), Karpas 422 (f), and RI-1 (g) cells.
Apoptotic cell death was measured as the percentage of Annexin V-
FITC-positive cells. Cells were pre-treated with U73122 (1 or 2.5 µM)
or U73343 (2.5 µM) for 30 min. Cell death was measured 24 h after
BIRD-2 treatment. Data are shown as the Δ apoptotic fraction, which is
the difference in apoptosis between the BIRD-2-treated and the
vehicle-treated fraction, and between the BIRD-2+U73122-treated
and the U73122-treated fraction, and ﬁnally between the BIRD-2+
U73343-treated and the U73343-treated fraction. Statistically sig-
niﬁcant differences were determined using an analysis of variance
(ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001)
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Discussion
The main ﬁnding of this study is that constitutive IP3 sig-
naling, besides high IP3R2-expression levels, is an important
determinant that underlies cancer cells’ addiction to Bcl-2 at
the ER Ca2+ stores. Constitutive IP3 signaling is therefore an
additional determinant of the sensitivity of B-cell cancers,
like DLBCL and CLL, to BIRD-2, a Bcl-2 inhibitor that
targets its BH4 domain and alleviates Bcl-2′s inhibitory role
on IP3R channels. As such, BIRD-2 can be applied as a tool
to exploit pro-survival constitutive IP3 signaling occurring in
B-cell cancers and switch it into pro-apoptotic signaling.
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BIRD-2 disrupts endogenous Bcl-2/IP3R complexes,
thereby triggering Ca2+-driven apoptosis in different
malignancies, including CLL [18, 20, 30], DLBCL [20],
multiple myeloma [31], follicular lymphoma [31], and small
cell lung cell carcinoma [32]. DLBCL cells displayed a
varying sensitivity to BIRD-2, which correlated to the
expression levels of IP3R2 [20]. Furthermore, a reciprocal
sensitivity between BIRD-2 and venetoclax has been
reported for DLBCL cells, indicating that cancer cells less
sensitive to BH3 mimetics are more sensitive to BIRD-2 and
vice versa [9]. Additionally, low BIRD-2 concentrations
sensitized DLBCL cells towards venetoclax by upregulating
the pro-apoptotic BH3-only protein Bim [9]. BIRD-2 also
sensitized multiple myeloma cells to BH3 mimetics through
a mechanism that involved the Ca2+-dependent upregulation
of Bim [31]. In this study, we also measured Bim expression
in SU-DHL-4 cells treated with higher concentrations of
BIRD-2 (Supplemental Fig. 2). After 24 h of treatment with
the IC50 value of BIRD-2 (10 µM), we observed a signiﬁcant
increase in Bim expression, suggesting that this BH3-only
protein may contribute to BIRD-2-triggered cytotoxicity.
However, further work is needed to elucidate the role of Bim
in BIRD-2-induced apoptosis.
It is well established that DLBCL and CLL cells display
chronic BCR signaling, leading to constitutive activation of
different signaling pathways, including the PLCγ2 pathway,
which leads to the production of IP3 in basal conditions [23–
25]. We here show that IP3 levels are likely elevated in SU-
DHL-4 cells, as a PLC inhibitor was able to lower basal [Ca2
+]. We also attempted to directly measure IP3 levels using an
IP3 FRET sensor [33], but the dynamic range of this sensor
appeared insufﬁcient to reliably assess a decrease in basal
IP3 levels using our microscopy systems. The role of con-
stitutive IP3 signaling in DLBCL cell survival requires
further study, since pharmacological PLC inhibition using
U73122 affected the survival of several DLBCL cell lines.
We anticipate that this is an on-target effect of U73122 on
PLC, since its inactive enantiomer U73433 did not display
this effect. These ﬁndings indicate a pro-survival role of
basal IP3/Ca
2+ signaling, but further work is needed to
document this in other B-cell cancers and lymphoprolifera-
tive malignancies. Nevertheless, these results converge with
ﬁndings obtained in solid tumors, showing that tumorigenic,
but not non-tumorigenic, cells depend on basal IP3R func-
tion for their survival [34–36]. In these cancer models, IP3Rs
provide a constitutive ER-mitochondrial Ca2+ ﬂux to drive
mitochondrial metabolism and the production of mitochon-
drial substrates needed for nucleotide synthesis critical for
cancer cell proliferation. Normal cells are less dependent on
IP3Rs for their survival, as they can tune down proliferation
to accommodate the compromised mitochondrial bio-
energetics [34–36]. However, further research is needed to
determine whether constitutive IP3 signaling and basal IP3R
function are both essential for B-cell cancer cell survival by
mediating ER-mitochondrial Ca2+ ﬂuxes that sustain mito-
chondrial metabolism, thereby accounting for U73122-
induced cell death [34, 35].
An important implication of this study is that although
IP3R2 expression is important for BIRD-2-induced apoptosis,
it is not sufﬁcient per se. It is clear that a constitutively
increased level of IP3, the ligand that activates IP3R channels,
is needed as well. Of interest, IP3R2 channels display the
highest IP3 sensitivity [22]. Thus, the combination of high
IP3R2-expression levels and constitutive IP3 signaling makes
DLBCL cells particularly addicted to Bcl-2 inhibition of IP3Rs
at the ER, and thus sensitive to BIRD-2. This is supported by
data obtained in primary hepatocytes, cells expressing rela-
tively high levels of IP3R2, but which are resistant to BIRD-2,
suggesting that IP3R2 alone is not sufﬁcient for BIRD-2
sensitivity. These data are of high importance, as IP3R2
channels are expressed in different organs and tissues in the
human body, where they exert important physiological func-
tions [22]. Our data therefore suggest that BIRD-2-derived or
BIRD-2-mimetic molecules may be well tolerated in the
human body and may not cause a general toxicity in normal
cells or tissues that express high IP3R2 levels.
The concept of constitutive IP3 signaling contributing to
BIRD-2 sensitivity was also observed in primary CLL
samples, where low concentrations of U73122 protected
against BIRD-2-induced apoptosis. In the ﬁrst place, we
focused on the cell-autonomous response of the CLL cells
towards BIRD-2. However, interactions with bystander cells
in micro-environmental niches support CLL cells by pro-
viding survival and proliferative signals [37–39]. Hence,
these unsupported experiments were restricted towards
short-term BIRD-2 application to limit spontaneous cell
death, correlating with loss of Bcl-2-family members such as
Fig. 7 PLC inhibition suppresses BIRD-2-induced cell death in a
subset of primary CLL patient cells. (a-d) Results from ﬂow cytometry
analysis of Annexin V-FITC/7-AAD-stained CLL patient samples
treated for 2 h with 30 µM BIRD-2 with or without U73122 pre-
treatment. For each CLL sample, the individual bar graph, plotting the
apoptotic fraction (%) measured in untreated cells (black bar), cells
treated with BIRD-2 (dark gray bar), U73122 (gray bar) or a combi-
nation of U73122 and BIRD-2 (light gray bar), is shown. The lowest
U73122 concentration for which an effect could be observed was used
(0.1/0.5/2.5 µM; see Supplemental Table 1). The CLL samples were
stratiﬁed in 4 categories, according to the CI calculated for the com-
bined treatment of U73122 and BIRD-2 and according to their sen-
sitivity towards U73122: (a) CI > 1.2 & cell death U73122 < 10%; (b)
CI > 1.2 and cell death U73122 > 10%; (c) 0.8 ≤ CI ≤ 1.2; (d) CI < 0.8.
At the bottom of each panel, the Δ apoptotic fraction (%), which
corresponds to the difference in apoptotic fraction between the BIRD-
2-treated and the control condition, and between the BIRD-2+
U73122-treated and the U73122-treated conditions, is shown for each
CLL sample belonging to that category. In the dot plots, each CLL
sample is represented with a different color, which is shown in the
titles of the individual bar graphs. Statistically signiﬁcant differences
were determined using a one-tailed paired t-test (**P < 0.01)
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anti-apoptotic Mcl-1 due to rapid loss of supportive signals
[37]. Therefore, we also performed experiments in CLL cells
supported by CD40L-expressing ﬁbroblasts. These co-
culture conditions protected against spontaneous apoptosis,
but did not antagonize BIRD-2-induced cell death. Fur-
thermore, PLC inhibition with U73122 remained capable of
suppressing BIRD-2-induced apoptosis in CLL cells irre-
spective of whether they were exposed to BIRD-2/U73122
in unsupported or co-cultured conditions.
We observed variability in the sensitivity of individual
CLL samples to BIRD-2, though the underlying mechan-
isms remain elusive. The BIRD-2 sensitivity of CLL cells
did not correlate to their BCR mutational status, suggesting
that basal IP3 signaling might be increased in B-cell cancers
irrespective of their BCR mutational status (Supplemental
Table 1). The varying BIRD-2 sensitivity could be due to
differences in IP3R2 expression, due to varying deﬁciencies
in regulators of IP3R function [40], or due to different
degrees of coupling between the ER and the mitochondria
[41]. For instance, phosphatase and tensin homolog (PTEN)
and protein kinase B (Akt/PKB) control Ca2+-dependent
apoptosis via IP3R3 [42–44]. Since reduced PTEN levels
have been reported in CLL, as well as in DLBCL [45, 46],
we measured PTEN expression in the primary CLL samples
and DLBCL cell lines used in this study. All CLL samples
expressed PTEN at similar levels (Supplemental Fig. 3a),
indicating that differences in PTEN expression do not
account for the varying BIRD-2 sensitivity of CLL cells.
Furthermore, PTEN was detected in SU-DHL-4, SU-DHL-6
and RI-1 cells, but not in Karpas 422 (Supplemental
Fig. 3b). Thus, BIRD-2 sensitivity of DLBCL cells appears
unrelated to PTEN expression, since both PTEN-proﬁcient
SU-DHL-4 and PTEN-deﬁcient Karpas 422 cells respond
well to BIRD-2 (IC50 values around 10 µM) [9].
Overall, our study indicates that constitutive IP3 signal-
ing, likely a pro-survival mechanism in B-cell malignancies,
is an important contributor for BIRD-2-induced apoptosis in
cancer cells that express high IP3R2 levels. Although IP3R2
Fig. 8 Pharmacological PLC
inhibition protects against
BIRD-2-induced apoptosis in
co-cultured CLL cells. a Results
from ﬂow cytometry analysis of
Annexin V-FITC/PI-stained
CLL samples that were either
unsupported or co-cultured with
CD40L-expressing ﬁbroblasts.
The co-cultured CLL cells were
treated for 20 h with vehicle or
30 µM BIRD-2 with or without
0.1 µM U73122 pre-treatment.
Data are shown as the
percentage of apoptotic cells
(%). For each CLL sample, the
CI calculated for U73122+
BIRD-2 treatment is indicated.
b Plot of the Δ apoptotic fraction
(%) for BIRD-2 and U73122+
BIRD-2 treatment of each CLL
sample in co-cultured
conditions. The Δ apoptotic
fraction corresponds to the
difference in apoptotic fraction
between the BIRD-2-treated and
the control condition, and
between the BIRD-2+U73122-
treated and the U73122-treated
conditions. Statistically
signiﬁcant differences were
determined using a one-tailed
paired t-test (**P < 0.01)
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is important for BIRD-2-induced cell death, its high
expression alone is not sufﬁcient per se for BIRD-2 sensi-
tivity. This is important given the pivotal physiological
functions of IP3R2 channels in normal tissues and cells.
Hence, Bcl-2 antagonism via the BH4 domain might be a
promising strategy to target B-cell cancers, in particular
those displaying high IP3R2-expression levels and con-
stitutive IP3 signaling.
Materials and methods
Reagents, antibodies, and constructs
Reagents were as follows: ethylene glycol tetraacetic acid
(EGTA) (Acros Organics, Geel, Belgium, 409910250),
Fura-2 AM (Biotium, Kampenhout, Belgium, 50033),
Annexin V-Fluorescein isothiocyanate (FITC) (Becton
Dickinson, Franklin Lakes, NJ, USA, 556419), 7-
aminoactinomycin D (7-AAD) (Becton Dickinson,
555815), U73122 (Enzo Life Sciences, Farmingdale, NY,
USA, BML-ST391-0005), U73343 (Enzo Life Sciences,
BML-ST392-0005), venetoclax (ChemieTek, Indianapolis,
IN, USA, CT-A199), anti-human IgG/M (Jackson Immu-
noResearch, West Grove, PA, USA, 109-006-127). The
following antibodies were used: anti-IP3R2 (Abiocode,
Agoura Hills, CA, USA, R2872-3); anti-calnexin (Enzo Life
Sciences, Farmingdale, NY, USA, ADI-SPA-865-D); anti-
Bcl-2 (Santa Cruz Biotechnology, Dallas, TX, USA,
sc7382HRP); anti-Bim (Bioké, Leiden, The Netherlands,
2819 S); anti-GAPDH (Sigma-Aldrich, St. Louis, MO,
USA, G8795); anti-vinculin (Sigma-Aldrich, Munich, Ger-
many, V9131). The sequences of the peptides used in this
study were: BIRD-2 (RKKRRQRRRGGNVYTEIKCNS
LLPLAAIVRV) and TAT-Ctrl (RKKRRQRRRGGSIELDD
PRPR). These peptides were synthesized by LifeTein (South
Plainﬁeld, New Jersey, USA) with a purity of at least 85%.
The IP3 sponge (pEF-GSTm49-IRES-GFP) is a protein
constructed from the IP3-binding core of the type 1 IP3R
with a single amino acid substitution (R441Q) that has a
very high afﬁnity for IP3 [29].
CLL patient samples
CLL was deﬁned by clinical examination of the patients and
immunophenotypic analysis of the blood samples. Only
samples where > 80% of the cells were CD19+were con-
sidered. The tumor immunoglobulin heavy chain variable
(IGHV) sequence was determined to designate the BCR
status (unmutated or mutated). The collection of blood
samples from CLL patients has been approved by the
ethical committee of the UZ Leuven (Belgian Number:
B3222001536) and by the ethical committee of the
Università Cattolica del Sacro Cuore, Fondazione Policli-
nico A. Gemelli, Rome, Italy (protocol number 14563/15).
Blood samples were collected according to the principles
established by the International Conference on Harmoni-
zation Guidelines on Good Clinical Practice. An informed
consent was obtained from all patients. Primary lympho-
cytes were separated using a Ficoll Hypaque density gra-
dient from the peripheral blood of adult patients with B-
CLL, and re-suspended in RPMI-1640 medium. For co-
culture experiments, human CLL cells (1 × 107/ml) were
cultured for 24 h in the presence of CD40L-expressing
ﬁbroblasts (2 × 104/condition), which were previously trea-
ted for 2 h with 10 µg/ml mitomycin C. The CLL co-
cultures were then pre-treated for 90 min with U73122 prior
to the addition of BIRD-2. After 20 h of BIRD-2 treatment,
CLL cells were collected and analyzed.
Cell culture
The SU-DHL-4, OCI-LY-1, Karpas 422, and SU-DHL-6
DLBCL cell lines were kindly obtained from Dr. Anthony
Letai (Dana-Farber Cancer Institute, Boston, Massachusetts,
USA). The RI-1 DLBCL cell line was obtained from DSMZ
(Braunschweig, Germany). All these cell lines were
authenticated by the University of Arizona Genetics Core
(Tucson, AZ, USA) using autosomal short tandem repeat
(STR) proﬁling utilizing the Science Exchange platform
(www.scienceexchange.com). All cell lines fully matched
the DNA ﬁngerprint present in reference databases, except
for SU-DHL-6 cells, which matched 7 out of 8 tested
alleles. OCI-LY-1 cells were cultured in suspension in
Iscove’s modiﬁed Dulbecco’s medium (Invitrogen, Mer-
elbeke, Belgium), while the other DLBCL cell lines were
cultured in suspension in RPMI-1640 medium (Invitrogen,
Merelbeke, Belgium). The human hepatocellular carcinoma
cell line HepG2 was cultured in Dulbecco’s Modiﬁed Eagle
medium (DMEM). Media were supplemented with 10%
heat-inactivated fetal bovine serum, L-glutamine (100 ×
GlutaMAX, Gibco/Invitrogen, 35050) and penicillin and
streptomycin (100 × Pen/Strep, Gibco/Invitrogen, 15070-
063). Cells were cultured at 37 °C in the presence of 5%
CO2. Primary hepatocytes were isolated from mice using a
two-step collagenase perfusion as previously described
[47]. Subsequently, the primary cells were cultured in
DMEM supplemented with 10% heat-inactivated fetal
bovine serum, L-glutamine, penicillin and streptomycin.
Cell transfection
Twenty-four hours after seeding, the indicated vectors were
introduced into the SU-DHL-4 cells utilizing the Amaxa®
Cell Line Nucleofector® Kit L (Lonza, Basel, Switzerland),
program C-05. Brieﬂy, 3 × 106 cells were transfected with 3
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μg of pEF-GSTm49-IRES-GFP (IP3 sponge vector), 3 μg
pcDNA3.1 (control vector), or 1.5 μg pmaxGFP® vector (to
assess transfection efﬁciency). GFP expression was
checked by ﬂow cytometry 24 h after transfection. A
pcDNA 3.1(-) mCherry expressing vector was co-
transfected at a 1:3 ratio as a selection marker for single-
cell cytosolic Ca2+ imaging.
Apoptosis assay
DLBCL cells (5 × 105 cells/ml) were treated as indicated,
pelleted by centrifugation, and incubated with Annexin V-
FITC/7-AAD or Annexin V-APC. Cell suspensions were
analyzed with an Attune® Acoustic Focusing Flow Cyt-
ometer (Applied Biosystems). Cell death by apoptosis was
scored by quantifying the population of Annexin V-FITC-
positive cells (blue laser; BL-1) or Annexin V-APC-positive
cells (red laser; RL-1). The latter was used in combination
with pEF-GSTm49-IRES-GFP. To assess the effect of
U73122 on BIRD-2-induced cell death, the Δ apoptotic
fraction was obtained by subtracting the % of cells under-
going cell death in U73122-treated conditions from the % of
cells undergoing cell death upon BIRD-2+U73122 treat-
ment. Flow-cytometric data were plotted and analyzed
using Attune version 2.1.0 (Applied Biosystems) or FlowJo
version 10 software. The CI was calculated in order to
determine mathematically whether a drug combination is
synergistic (CI < 0.8), additive (0.8 ≤CI ≤ 1.2), or antag-
onistic (CI > 1.2). The CI was determined by making the
ratio of the sum of the individual effects (EffectCompound A+
EffectCompound B) with the effect of the combined treatment
(EffectCompound A+ Compound B).
Western-blot analysis
Cells were washed with phosphate-buffered saline and
incubated at 4 °C with lysis buffer (25 mM HEPES, pH 7.5,
1% Triton X-100, 300 mM NaCl, 1.5 mM MgCl2, 10%
glycerol, 2 mM EDTA, 2 mM EGTA, 1 mM dithiothreitol,
and protease inhibitor tablets (Roche, Basel, Switzerland))
for 30 min on a head-over-head rotor. Cell lysates were
centrifuged for 5 min at 10,000 r.p.m. and analyzed by
western blotting as previously described [16]. Microsomes
were prepared from primary hepatocyte as previously
described [48].
Basal [Ca2+]cyt measurements
Basal Ca2+ levels were monitored with the cytosolic Ca2+
indicator Fura-2 AM. Cells (10 × 106/sample) were loaded
for 30 min with 1.25 µM Fura-2 AM at room temperature in
modiﬁed Krebs solution (containing 150 mM NaCl, 5.9 mM
KCl, 1.2 mM MgCl2, 11.6 mM HEPES (pH 7.3), 11.5 mM
glucose and 1.5 mM CaCl2), followed by a de-esteriﬁcation
step of 30 min in the absence of Fura-2 AM. During the de-
esteriﬁcation step, cells were treated with vehicle, U73343
(1 and 2.5 µM) or U73122 (1 and 2.5 µM). Fluorescence
was monitored on a luminescence spectrometer (AMINCO-
Bowman Series 2, Spectronic Unicam) by alternately
exciting the Ca2+ indicator at 340 and 380 nm and col-
lecting emitted ﬂuorescence at 510 nm. Basal [Ca2+]cyt was
derived after in situ calibration according to the Grynkie-
wicz equation: [49]
Ca2þ
 
cyt nMð Þ ¼ Kd  q
R Rmin
Rmax  R
Kd is the dissociation constant of Fura-2 for Ca
2+ at room
temperature (241 nM), q is the ﬂuorescence ratio of the
emission intensity in the absence of Ca2+ (F380 max), to that
in the presence of saturating Ca2+ (F380 min), R is the
ﬂuorescence ratio, and Rmin and Rmax are the minimal and
maximal ﬂuorescence ratios, respectively. Rmax was
obtained by administrating 50 µM digitonin, subsequently
Rmin was measured by adding 33 mM EGTA in Ca
2+-free
modiﬁed Krebs solution.
Ca2+ measurements in cell populations
To perform Ca2+ measurements in intact cells, DLBCL cells
were seeded in poly-L-lysine-coated 96-well plates (Greiner)
at a density of 5 × 105 cells/ml. The cells were loaded for
30 min with 1.25 µM Fura-2 AM at 25 °C in modiﬁed Krebs
solution, followed by a 30min de-esteriﬁcation step in the
absence of Fura-2 AM. Fluorescence was monitored on a
FlexStation 3 microplate reader (Molecular Devices, Sun-
nyvale, CA, USA) by alternately exciting the Ca2+ indicator
at 340 and 380 nm and collecting emitted ﬂuorescence at
510 nm, as described previously [50]. All data were obtained
in triplicate and are plotted as F340/F380. At least three
independent experiments were performed.
Single-cell Ca2+ imaging
The IP3 sponge and mCherry constructs were introduced
into SU-DHL-4 cells as described above. A Zeiss Axio
Observer Z1 Inverted Microscope equipped with a 20x air
objective and a high-speed digital camera (Axiocam Hsm,
Zeiss, Jena, Germany) were used for these measurements.
Fura-2 AM measurements were performed as previously
described [15].
Statistical analysis
Results are expressed as average ± SD or SEM as indicated.
The number of independent experiments is always indi-
cated. Signiﬁcance was determined using a one-tailed or
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two-tailed paired Student’s t-test or an analysis of variance
(ANOVA) as appropriate. Differences were considered
signiﬁcant at P < 0.05.
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